Evolus, Inc. (EOLS) Reports Q3 Loss, Beats Revenue Estimates
Evolus, Inc. (EOLS) came out with a quarterly loss of $0.14 per share versus the Zacks Consensus Estimate of a loss of $0.19. This compares to a loss of $0.19 per share a year ago.
Will Evolus, Inc. (EOLS) Report Negative Earnings Next Week? What You Should Know
Evolus (EOLS) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Evolus, Inc. (EOLS) Reports Q2 Loss, Lags Revenue Estimates
Evolus, Inc. (EOLS) came out with a quarterly loss of $0.24 per share versus the Zacks Consensus Estimate of a loss of $0.09. This compares to a loss of $0.07 per share a year ago.
Evolus, Inc. (EOLS) Q2 2025 Earnings Call Transcript
Evolus, Inc. (NASDAQ:EOLS ) Q2 2025 Earnings Conference Call August 5, 2025 4:30 PM ET Company Participants David Moatazedi - President, CEO & Director Nareg Sagherian - Head of Global Investor Relations & Corporate Communications Rui Avelar - Chief Medical Officer and Head of Research & Development Conference Call Participants Annabel Eva Samimy - Stifel, Nicolaus & Company, Incorporated, Research Division Douglas Dylan Tsao - H.C. Wainwright & Co, LLC, Research Division Marc Harold Goodman - Leerink Partners LLC, Research Division Navann Ty Dietschi - BNP Paribas Exane, Research Division Sam Shimon Eiber - BTIG, LLC, Research Division Serge D.
Earnings Preview: Evolus, Inc. (EOLS) Q2 Earnings Expected to Decline
Evolus (EOLS) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Evolus - A Slightly Risky Buy Ahead Of Q2 Earnings
I maintain my Buy rating on Evolus, confident in management's guidance and optimistic about Q2 earnings exceeding Wall Street expectations. Evolus is demonstrating strong market share gains, successful new product launches, and reaffirmed 2025 revenue guidance despite recent share price volatility. Key risks include exposure to potential US tariffs, reliance on overseas manufacturers, and competitive pressures from established players like AbbVie's Botox.
Evolus, Inc. (EOLS) Reports Q1 Loss, Misses Revenue Estimates
Evolus, Inc. (EOLS) came out with a quarterly loss of $0.18 per share versus the Zacks Consensus Estimate of a loss of $0.10. This compares to loss of $0.13 per share a year ago.
Evolus, Inc. (EOLS) Q1 2025 Earnings Call Transcript
Evolus, Inc. (NASDAQ:EOLS ) Q1 2025 Earnings Conference Call May 7, 2025 4:30 PM ET Company Participants Nareg Sagherian - VP, Head of Global IR and Corporate Communications David Moatazedi - President and CEO Sandra Beaver - CFO Conference Call Participants Annabel Samimy - Stifel Marc Goodman - Leerink Partners Navann Ty - BNP Paribas Serge Belanger - Needham Doug Tsao - H.C. Wainwright Sam Eiber - BTIG Operator Good afternoon, everyone.
Will Evolus, Inc. (EOLS) Report Negative Earnings Next Week? What You Should Know
Evolus (EOLS) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Evolus, Inc. (EOLS) Q4 2024 Earnings Call Transcript
Evolus, Inc. (NASDAQ:EOLS ) Q4 2024 Earnings Conference Call March 4, 2025 4:30 PM ET Company Participants Nareg Sagherian - VP and Head of Global IR and Corporate Communications David Moatazedi - President and CEO Rui Avelar - Chief Medical Officer and Head of R&D Sandra Beaver - CFO Conference Call Participants Annabel Samimy - Stifel Gangireddy Madhumitha - Stryker Navann Ty - BNP Paribas Doug Tsao - H.C. Wainwright Serge Belanger - Needham & Company Operator Good afternoon, everyone, and thank you for standing by.
Evolus, Inc. (EOLS) Q4 Earnings and Revenues Lag Estimates
Evolus, Inc. (EOLS) came out with quarterly earnings of $0.01 per share, missing the Zacks Consensus Estimate of $0.06 per share. This compares to loss of $0.14 per share a year ago.
Evolus posts quarterly profit on strong sales of cosmetic injection
Cosmetic drugmaker Evolus reported a fourth-quarter profit versus a year-ago loss on Tuesday, on strong demand for its wrinkle treatment Jeuveau which competes with Botox.
